Laura Melancon started as a patient here at the age of 23. Now, years later, Laura has come back to the Cancer Center to work as a Bone Marrow Transplant Coordinator.
Explore the Bone Marrow Transplant Program
Mass General Cancer Center's Bone Marrow Transplant (BMT) Program is world-renowned for its expertise in hematopoietic cell transplantation (HCT) to treat a wide variety of hematological conditions. Since the BMT program’s inception in 1992, we have conducted over 3,000 transplant procedures and currently conduct over 150 transplant procedures annually. In addition to comprehensive and compassionate multi-disciplinary care for our patients, we also conduct leading-edge clinical and translational research to develop innovative strategies for improving the outcomes of patients undergoing BMT.
Our program is advancing clinical care and research in several areas and these include:
Reducing the toxicities of BMT:
- Development of new strategies for reducing both acute and chronic transplant related toxicities
- Analysis of patient-reported outcomes including quality of life of our patients undergoing BMT and developing new interventions to improve the experience of both patients and their caretakers
- BMT Survivorship program to better address the long-term health needs of patients after transplant
Novel treatment approaches against graft-vs-host disease (GVHD):
- Participation in national consortiums and clinical trials studying acute and chronic GVHD
- Development of new therapies to prevent acute and chronic GVHD
- Development of new therapies to treat acute and chronic GVHD
Developing safer and more effective stem cell transplant protocols for patients who do not have a fully matched related or unrelated donor:
- Innovative protocols involving haploidentical donors (partially matched relatives) or partially match unrelated donors
Reducing disease relapse after stem cell transplantation:
- Study the use of maintenance therapies after allogeneic transplantation to reduce disease relapse
Increasing tolerance for solid organ transplants by performing combined kidney and bone marrow transplants for patients who have both advanced kidney disease and an underlying blood disease.
Multidisciplinary Patient Care
At Mass General Cancer Center, we pride ourselves in providing excellent, comprehensive clinical care to patients undergoing transplant. Embedded within Massachusetts’ oldest teaching hospital, our program offers the top-notch multidisciplinary care, resources and expertise needed to achieve successful outcomes. The size of our program has allowed us to foster specialization and expertise in the field of HCT, yet maintain the continuity and personal relationships that have always been a Mass General standard. We look forward to working with you.
Providing state of the art clinical care through innovative research is a foundational principle of our BMT program. Clinical trials are research studies which are conducted to answer questions that help advance the care of patients. They can test many things from new drugs, new combinations of drugs, already approved drugs being studied to treat patients in new or different ways or investigating novel approaches to treat specific patients in unique circumstances. The Mass General Bone Marrow Transplant Program has a very active clinical research portfolio with investigational studies covering almost all aspects of transplant care. The ultimate goal of clinical research is to improve the outcomes for all of our patients.
We believe collaboration with other transplant centers is key to conducting impactful research. Our program has long-standing collaborations with established centers and consortiums, including:
- The Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
- The Center for International Blood and Marrow Transplant Research (CIBMTR)
- The Mount Sinai Acute GVHD Consortium (MAGIC)
We are proud to have participated in practice-changing clinical trials, which have resulted in FDA approval of treatments for GVHD, including:
- Ruxolitinib for steroid-refractory acute GVHD
- Belumosudil for steroid-refractory chronic GVHD
- Ruxolitinib for steroid-refractory chronic GVHD
Our program has also had a pivotal role in a number of recent innovative clinical trials investigating novel approaches to multiple aspects of BMT care. These trials have included:
- Anti-T-lymphocyte globulin to prevent chronic graft-versus-host disease
- Fecal microbiota transplant to restore the intestinal microbiome after allogeneic transplant
- α-1-antitrypsin to prevent steroid-refractory graft-versus-host disease in high-risk patients
- Vedolizumab to prevent acute GI graft-versus-host disease
Acute GVHD Treatment
Chronic GVHD Treatment
Maintenance Therapy after Transplant
- Sorafenib maintenance to prevent relapse for FLT3+ AML
- Enasidenib maintenance to prevent relapse for IDH2-mutated myeloid diseases
Combined Kidney and Bone Marrow Transplant
Palliative Care and Transplant Survivorship
If you are eligible for a clinical trial, your physician will offer you the chance for participation. We will comprehensively review the logistics and purpose of the trial and also offer alternatives including the standard of care.
Meet the Team
Our BMT team's multidisciplinary approach to evaluation, management, and treatment provides each patient with individually tailored care.
- Director, Hematopoietic Cell Transplant & Cell Therapy Program
- Allen B. Rogers, Jr. and Cara J. Rogers Endowed Chair
- Professor of Medicine, Harvard Medical School
- Director, BMT Clinical Research
- Assistant Professor of Medicine, Harvard Medical School
- Associate Director, Cancer Outcomes Research and Education Program
- Director, Bone Marrow Transplant Survivorship Program
- Associate Professor of Medicine
- Clinical Director, Bone Marrow Transplant Program
- Assistant Professor of Medicine, Harvard Medical School
What is a Bone Marrow Transplant? You may also hear this procedure called a “hematopoietic stem cell transplant.” This procedure can be either autologous or allogeneic. In an autologous bone marrow transplant, patients receive their own stem cells. In an allogeneic bone marrow transplant, patients receive donor stem cells.
Helps to identify & provide care for families that have hereditary risk for blood cancers.
Take a tour of the Bone Marrow Transplant Unit at the Mass General Cancer Center.
Learn about the types of blood cells, what they do, and how they are measured.
Learn more about taking care of yourself after an allogeneic bone marrow transplant.
Tour the Bone Marrow Transplant Unit on Lunder 10
Take a tour of the Bone Marrow Transplant Unit at the Mass General Cancer Center. Learn all about the unit, including the services and amenities you and your loved ones can expect during your stay here.
Honors & Awards
View BMT team members honored for their commitment to the fight against cancer.
Yi-Bin Chen, MD
Patients and their families revere Yi-Bin Chen, MD, a clinician and researcher at the Mass General Cancer Center who specializes in bone marrow-stem cell transplantation.
Areej El-Jawahri, MD
Every day, people from around the world are making real progress in the fight against cancer. Areej El-Jawahri, MD, is among the forefront of this group, developing innovations that are far-reaching and impactful.
Timothy Graubert, MD
Timothy Graubert, MD, is a leading researcher in the study of hematologic malignancies. Dr. Graubert’s laboratory seeks to gain insight into the biological basis of myeloid leukemias and to improve strategies for diagnosis, risk stratification and targeted therapy.
Marcela Maus, MD, PhD
As the director of the Cellular Immunotherapy Program at the Mass General Cancer Center, Marcela Maus, MD, PhD, is following a childhood dream of fixing genes gone wrong in the pursuit of a cure for cancer.
Steven McAfee, MD
"Everyone we came into contact with at the Mass General Cancer Center was wonderful to us. However, Dr. McAfee stands out as the most dedicated, caring and loving person I have ever met."
Thomas Spitzer, MD
An expert clinician, teacher and researcher, Dr. Spitzer specializes in treating leukemia and other blood cancers which are often treated with bone marrow transplantation—and has contributed much knowledge to this field.
Caring For A Cure
Inspired by small acts of kindness, Caring For A Cure was founded by the nurses of the Mass General Adult Hematology/Oncology and Bone Marrow Transplant program with a goal to improve the journey of patients and families with cancer through research, resources, and awareness.
Related News and Articles
- Patient Story
- Mar | 26 | 2019
Robbie and John are both patients here at the Mass General Cancer Center. Robbie and John have decided to face the challenges that come with each of their diagnoses’ together.